Indeed, passive immunotherapy with antibody targeting the N-terminal projection domain of human tau has been proved to be beneficial in improving cognitive deficits in AD transgenic mice [132,133,134] suggesting that the targeting of pathological tau is a promising disease-modifying cure for tauopathies in the near future. Here, MAPT is linked to tauopathy.